Dinutuximab
Mechanism :
Dinutuximab binds to the disialoganglioside GD2, which is highly expressed in neuroblastoma, most melanomas, and other tumors, as well as on normal tissues such as neurons, skin melanocytes, and peripheral sensory nerve fibres. Dinutuximab induces cell lysis (of GD2-expressing cells) through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity.
Indication :
Contraindications :
History of anaphylaxis to dinutuximab.
Dosing :
IV
17.5 mg/m²/day for 4 consecutive days for a maximum of 5 cycles (in combination with GM-CSF, IL-2 and 13-cis-retinoic acid. Infuse on days 4, 5, 6, and 7 during cycles 1, 3, and 5 (cycles 1, 3, and 5 are 24 days in duration); infuse on days 8, 9, 10, and
Adverse Effect :
Pain, pyrexia, edema, thrombocytopenia, lymphopenia, anemia, neutropenia, hypotension, capillary leak syndrome, hypertension, hyponatremia, hypokalemia, hypoalbuminemia, hypocalcemia, hypophosphatemia, hyperglycemia, hypertriglyceridemia, decreased appetite, hypomagnesemia, increased alanine aminotransferase, increased serum creatinine, increased weight, vomiting, diarrhea, nausea, urticaria, hypoxia, tachycardia, sepsis, device-related infection, proteinuria, peripheral neuropathy.
Interaction :
Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines.
Hepatic Dose :
Specific guidelines for dosage adjustments in hepatic impairment are not available.